| Patent application number | Description | Published |
|---|
| 20110033794 | TONER, METHOD FOR PRODUCING THE SAME, AND PROCESS CARTRIDGE - A toner containing a binder, a colorant, and a wax having a molecular chain consisting of C—H bond and C—C bond, wherein the mass reduction of the wax at 165° C. is 10% by mass or less, and the total amount of the wax in the toner measured by a DSC method is 1% by mass to 8% by mass, wherein a ratio, Sbet/SF, of a BET specific surface area (Sbet) of the toner to an average circularity (SF) of the toner is 1.0 m | 02-10-2011 |
| 20110255899 | TONER, DEVELOPER, TONER CONTAINER, PROCESS CARTRIDGE AND IMAGE FORMING APPARATUS - A toner, including a binder; a colorant; and a wax including a molecular chain constituted of only a C—H bond and a C—C bond, and having a melting point of from 50 to 78° C. and a melt viscosity of from 5 to 15 mPa·S at 140° C., wherein the toner has a weight reduction rate of from 0.001 to 0.1% by weight/min when measured by TGA (Thermogarvimetric Analysis) method in an atmosphere at 165° C. for 10 min. | 10-20-2011 |
| 20110262856 | TONER CONTAINING CRYSTALLINE POLYESTER - A toner including a binder resin which contains a crystalline polyester resin and a non-crystalline polyester resin, wherein the crystalline polyester resin has at least two diffraction peaks in a range of 20°<2θ<25° as detected by X-ray diffraction measurement, and has a melting point which is 60° C. or higher but lower than 80° C., and wherein the diffraction peaks each have a half width which is less than 1.0°. | 10-27-2011 |
| Patent application number | Description | Published |
|---|
| 20100003254 | Antibody Substituting for Function of Blood Coagulation Factor VIII - The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII. | 01-07-2010 |
| 20110098450 | Antibody Molecules - The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions. | 04-28-2011 |
| 20110245473 | Anti-IL-6 Receptor Antibody - The present inventors succeeded in discovering specific amino acid mutations in the variable region, framework region, and constant region of TOCILIZUMAB, and this enables to reduce immunogenicity risk and the heterogeneity originated from disulfide bonds in the hinge region, as well as to improve antigen binding activity, pharmacokinetics, stability under acidic conditions, and stability in high concentration preparations. | 10-06-2011 |
